It's crucial to store these liposomes at 4°C in the dark to maintain their stability. They should not be frozen as freezing can disrupt the liposomal structure, potentially affecting their performance.
When preparing these liposomes for experiments, ensure that they are thoroughly mixed and homogenized. The method of adding the therapeutic agent (e.g., nucleic acids or drugs) should be carefully chosen based on the type of agent and the desired encapsulation efficiency.
Yes, these liposomes can be used in conjunction with other substances. However, it's important to assess the compatibility of these substances with the liposomes to ensure that they do not destabilize the liposomal structure or interfere with the encapsulation and release of the therapeutic agent.
For transfection applications, consider the lipid-to-DNA ratio, the health and type of cells being transfected, and the incubation conditions. Optimizing these parameters is crucial for maximizing transfection efficiency.
The success can be evaluated by assessing the therapeutic response, which may include measuring the levels of delivered drug or gene expression in the target cells. Techniques such as fluorescence microscopy, PCR, and cell viability assays are commonly used.
Antigen uptake by CD11c+ DCs in NALTs following intranasal administration of Alexa Fluor-labelled OVA plus the cationic liposomes.
The study focused on the potent mucosal adjuvant effect of DOTAP/chol liposomes on intranasal immunization in mice. Vaccines administered through the mucosal route have the potential to be an effective strategy for combating infectious diseases, as mucosal surfaces serve as the primary entry point for most pathogens. For the intranasal administration of ovalbumin (OVA), researchers prepared cationic liposomes with DOTAP and cholesterol. They used flow cytometry to analyze OVA (Alexa Fluor 488-labeled) uptake by dendritic cells (DCs) in nasal-associated lymphoid tissues (NALTs) following intranasal administration of OVA-loaded liposomes or OVA alone. This makes it easier to determine if cationic liposomes may trigger antigen-specific humoral immune responses in the systemic and mucosal tissues. The administration of Alexa Fluor 488-OVA with DOTAP/chol liposomes led to a greater uptake of Alexa Fluor 488-OVA in DCs of NALTs compared to administration of Alexa Fluor 488-OVA alone. This indicates that DOTAP/chol liposomes have the potential to act as mucosal adjuvants and can enhance OVA transport to NALTs.
Tada, Rui, et al. "Intranasal immunization with DOTAP cationic liposomes combined with DC-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice." PLoS One 10.10 (2015): e0139785. Under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
Online Inquiry